Fara Brasó-Maristany

Grupo de investigación

Genómica traslacional y terapias dirigidas en tumores sólidos Assistant researcher (R2C)

fbraso@recerca.clinic.cat 0000-0001-5440-9643

Publicaciones destacadas

Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer

Autores:
Prat, Aleix; Guarneri, Valentina; Pascual, Tomas; Braso-Maristany, Fara; Sanfeliu, Esther;

(...)

Vivancos, Ana; Villagrasa, Patricia; Parker, Joel S; Conte, Pierfranco; Perou, Charles M.

Referencia: EBioMedicine 2022.
Gene expression profiles of breast cancer metastasis according to organ site

Autores:
Braso-Maristany, Fara; Pare, Laia; Chic, Nuria; Martinez-Saez, Olga; Pascual, Tomas;

(...)

Adamo, Barbara; Moreno, Reinaldo; Vidal, Maria; Munoz, Montserrat; Prat, Aleix.

Referencia: Molecular Oncology 2022.
Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer

Autores:
Braso-Maristany, Fara; Sanso, Miriam; Chic, Nuria; Martinez, Debora; Gonzalez-Farre, Blanca;

(...)

Peg, Vicente; Saura, Cristina; Munoz, Montserrat; Prat, Aleix; Vivancos, Ana.

Referencia: Frontiers in Oncology 2021.
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy: ER activity in pre-menopausal HR+ breast cancer during CT

Autores:
Chic, Nuria; Schettini, Francesco; Braso-Maristany, Fara; Sanfeliu, Esther; Adamo, Barbara;

(...)

Munoz, Montserrat; Perou, Charles M; Pascual, Tomas; Bellet, Meritxell; Prat, Aleix.

Referencia: EBioMedicine 2021.
Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies

Autores:
Prat, Aleix; Chaudhury, Anwesha; Solovieff, Nadia; Pare, Laia; Martinez, Debora;

(...)

Braso-Maristany, Fara; Lteif, Agnes; Taran, Tetiana; Babbar, Naveen; Su, Fei.

Referencia: JOURNAL OF CLINICAL ONCOLOGY 2021.
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy

Autores:
Martinez-Saez, Olga; Pascual, Tomas; Braso-Maristany, Fara; Chic, Nuria; Gonzalez-Farre, Blanca;

(...)

Salvador, Fernando; Ciruelos, Eva M; Faull, Iris; Odegaard, Justin I; Prat, Aleix.

Referencia: NPJ Breast Cancer 2021.
A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer

Autores:
Prat, Aleix; Tsai, Yi-Hsuan; Pascual, Tomas; Pare, Laia; Adamo, Barbara;

(...)

Brase, Jan Christoph; Rodrik-Outmezguine, Vanessa; Johnston, Stephen; Ciruelos, Eva; Parker, Joel S.

Referencia: CLINICAL CANCER RESEARCH 2020.
ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer

Autores:
Griguolo, Gaia; Braso-Maristany, Fara; Gonzalez-Farre, Blanca; Pascual, Tomas; Chic, Nuria;

(...)

Dieci, Maria Vittoria; Conte, Pierfranco; Harbeck, Nadia; Guarneri, Valentina; Prat, Aleix.

Referencia: Cancers 2020.
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

Autores:
Braso-Maristany, Fara; Griguolo, Gaia; Pascual, Tomas; Pare, Laia; Nuciforo, Paolo;

(...)

Gomis, Roger R; Villagrasa, Patricia; Cortes, Javier; Ciruelos, Eva; Prat, Aleix.

Referencia: Nature Communications 2020.
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

Autores:
Prat, Aleix; Pascual, Tomas; De Angelis, Carmine; Gutierrez, Carolina; Llombart-Cussac, Antonio;

(...)

Conte, PierFranco; Schiff, Rachel; Guarneri, Valentina; Osborne, C Kent; Rimawi, Mothaffar F.

Referencia: Journal of the National Cancer Institute 2020.

Proyectos destacados

Identification and validation of therapeutic targets to overcome resistance to CDK4/6 inhibitors in metastatic hormone receptor-positive HER2-negative breast cancer.

Investigador/a principal: Fara Brasó Maristany

Financiador: Fundación Científica Asociación Española Contra el Cáncer (AECC).

Código: INVES21943BRAS

Duración: 01/12/2021 - 30/11/2024
Estudio de los mecanismos de sensibilidad y resistencia al doble bloqueo HER2 y a las combinaciones con enzalutamida o palbociclib en modelos preclínicos de cáncer de mama HER2-positivo

Investigador/a principal: Aleix Prat

Financiador: Asociación Española Contra el Cáncer (AECC)

Código: Ayuda Postdoctoral AECC 2017

Duración: 01/11/2017 - 31/10/2021

Web: https://www.aecc.es/es/investigacion/proyectos-aecc/estudio-mecanismos-sensibilidad-resistencia-doble-bloqueo-her2-combinaciones-con-enzalutamida-o-palbociclib-modelos-preclinicos-cancer-mama-her2

Fara Brasó-Maristany

Grupo de investigación

Publicaciones destacadas

Proyectos destacados

Identification and validation of therapeutic targets to overcome resistance to CDK4/6 inhibitors in metastatic hormone receptor-positive HER2-negative breast cancer.

Estudio de los mecanismos de sensibilidad y resistencia al doble bloqueo HER2 y a las combinaciones con enzalutamida o palbociclib en modelos preclínicos de cáncer de mama HER2-positivo

Suscríbete a la Newsletter del Clínic